News | Coronavirus (COVID-19) | August 23, 2021

Pfizer-BioNTech COVID-19 Vaccine Gets Full Approval from FDA

Approval signifies key achievement for public health

#breakingnews The U.S. Food and Drug Administration (FDA) just granted full approval to the Pfizer/BioNTech Covid-19 vaccine for people age 16 and older. It is the first vaccine to be fully approved by the FDA, and experts say it is expected to open the door for further vaccine mandates.

Getty Images


August 23, 2021 — The U.S. Food and Drug Administration (FDA) just granted full approval to the Pfizer/BioNTech COVID-19 vaccine for people age 16 and older. It is the first vaccine to be fully approved by the FDA, and experts say it is expected to open the door for further vaccine mandates.

In December 2020, the U.S. Food and Drug Administration (FDA) issued the first emergency use authorization (EUA) for the COVID-19 vaccine submitted by Pfizer Inc. in partnership with BioNTech Manufacturing GmbH. It was the first vaccine to gain an FDA clearance for use.

The Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) is a suspension for intramuscular injection administered as a series of two doses (0.3 mL each) 3 weeks apart.

On August 23, the FDA issued the following statement:

Today, the U.S. Food and Drug Administration approved the first COVID-19 vaccine. The vaccine has been known as the Pfizer-BioNTech COVID-19 Vaccine, and will now be marketed as Comirnaty (koe-mir’-na-tee), for the prevention of COVID-19 disease in individuals 16 years of age and older. The vaccine also continues to be available under emergency use authorization (EUA), including for individuals 12 through 15 years of age and for the administration of a third dose in certain immunocompromised individuals.

“The FDA’s approval of this vaccine is a milestone as we continue to battle the COVID-19 pandemic. While this and other vaccines have met the FDA’s rigorous, scientific standards for emergency use authorization, as the first FDA-approved COVID-19 vaccine, the public can be very confident that this vaccine meets the high standards for safety, effectiveness, and manufacturing quality the FDA requires of an approved product,” said Acting FDA Commissioner Janet Woodcock, M.D. “While millions of people have already safely received COVID-19 vaccines, we recognize that for some, the FDA approval of a vaccine may now instill additional confidence to get vaccinated. Today’s milestone puts us one step closer to altering the course of this pandemic in the U.S.” 

Since Dec. 11, 2020, the Pfizer-BioNTech COVID-19 Vaccine has been available under EUA in individuals 16 years of age and older, and the authorization was expanded to include those 12 through 15 years of age on May 10, 2021. EUAs can be used by the FDA during public health emergencies to provide access to medical products that may be effective in preventing, diagnosing, or treating a disease, provided that the FDA determines that the known and potential benefits of a product, when used to prevent, diagnose, or treat the disease, outweigh the known and potential risks of the product.

FDA-approved vaccines undergo the agency’s standard process for reviewing the quality, safety and effectiveness of medical products. For all vaccines, the FDA evaluates data and information included in the manufacturer’s submission of a biologics license application (BLA). A BLA is a comprehensive document that is submitted to the agency providing very specific requirements. For Comirnaty, the BLA builds on the extensive data and information previously submitted that supported the EUA, such as preclinical and clinical data and information, as well as details of the manufacturing process, vaccine testing results to ensure vaccine quality, and inspections of the sites where the vaccine is made. The agency conducts its own analyses of the information in the BLA to make sure the vaccine is safe and effective and meets the FDA’s standards for approval. 

Comirnaty contains messenger RNA (mRNA), a kind of genetic material. The mRNA is used by the body to make a mimic of one of the proteins in the virus that causes COVID-19. The result of a person receiving this vaccine is that their immune system will ultimately react defensively to the virus that causes COVID-19. The mRNA in Comirnaty is only present in the body for a short time and is not incorporated into - nor does it alter - an individual’s genetic material. Comirnaty has the same formulation as the EUA vaccine and is administered as a series of two doses, three weeks apart. 

“Our scientific and medical experts conducted an incredibly thorough and thoughtful evaluation of this vaccine. We evaluated scientific data and information included in hundreds of thousands of pages, conducted our own analyses of Comirnaty’s safety and effectiveness, and performed a detailed assessment of the manufacturing processes, including inspections of the manufacturing facilities,” said Peter Marks, M.D., Ph.D., director of FDA’s Center for Biologics Evaluation and Research. “We have not lost sight that the COVID-19 public health crisis continues in the U.S. and that the public is counting on safe and effective vaccines. The public and medical community can be confident that although we approved this vaccine expeditiously, it was fully in keeping with our existing high standards for vaccines in the U.S."

FDA Evaluation of Safety and Effectiveness Data for Approval for 16 Years of Age and Older

The first EUA, issued Dec. 11, for the Pfizer-BioNTech COVID-19 Vaccine for individuals 16 years of age and older was based on safety and effectiveness data from a randomized, controlled, blinded ongoing clinical trial of thousands of individuals. 

To support the FDA’s approval decision today, the FDA reviewed updated data from the clinical trial which supported the EUA and included a longer duration of follow-up in a larger clinical trial population. 

Specifically, in the FDA’s review for approval, the agency analyzed effectiveness data from approximately 20,000 vaccine and 20,000 placebo recipients ages 16 and older who did not have evidence of the COVID-19 virus infection within a week of receiving the second dose. The safety of Comirnaty was evaluated in approximately 22,000 people who received the vaccine and 22,000 people who received a placebo 16 years of age and older.

Based on results from the clinical trial, the vaccine was 91% effective in preventing COVID-19 disease. 

More than half of the clinical trial participants were followed for safety outcomes for at least four months after the second dose. Overall, approximately 12,000 recipients have been followed for at least 6 months.

The most commonly reported side effects by those clinical trial participants who received Comirnaty were pain, redness and swelling at the injection site, fatigue, headache, muscle or joint pain, chills, and fever. The vaccine is effective in preventing COVID-19 and potentially serious outcomes including hospitalization and death.

Additionally, the FDA conducted a rigorous evaluation of the post-authorization safety surveillance data pertaining to myocarditis and pericarditis following administration of the Pfizer-BioNTech COVID-19 Vaccine and has determined that the data demonstrate increased risks, particularly within the seven days following the second dose. The observed risk is higher among males under 40 years of age compared to females and older males. The observed risk is highest in males 12 through 17 years of age. Available data from short-term follow-up suggest that most individuals have had resolution of symptoms. However, some individuals required intensive care support. Information is not yet available about potential long-term health outcomes. The Comirnaty Prescribing Information includes a warning about these risks.

Ongoing Safety Monitoring

The FDA and Centers for Disease Control and Prevention have monitoring systems in place to ensure that any safety concerns continue to be identified and evaluated in a timely manner. In addition, the FDA is requiring the company to conduct postmarketing studies to further assess the risks of myocarditis and pericarditis following vaccination with Comirnaty. These studies will include an evaluation of long-term outcomes among individuals who develop myocarditis following vaccination with Comirnaty. In addition, although not FDA requirements, the company has committed to additional post-marketing safety studies, including conducting a pregnancy registry study to evaluate pregnancy and infant outcomes after receipt of Comirnaty during pregnancy.

The FDA granted this application Priority Review. The approval was granted to BioNTech Manufacturing GmbH.

 

Vaccine Development 101 Explained by the FDA

FDA Issues Alert Regarding SARS-CoV-2 Viral Mutation to Healthcare Providers — Updated January 2021
 

Related COVID Radiology Content:

Special Storage and Adverse Reactions for First COVID-19 Vaccine Approved by the FDA

Lung Ultrasounds Could Help Determine COVID-19 Outcome

Johns Hopkins Medicine Expert Weighs Devastating Impact of COVID-19 on Healthcare Workers

CT in a Box Helps Rapidly Boost Imaging Capability at COVID Surge Hospitals

Philips Patient Management Solution keeps patients safe and personalizes care during COVID-19 at leading U.S. medical centers

 

CT Imaging of the 2019 Novel Coronavirus (2019-nCoV) Pneumonia

Infervision in the Frontlines Against the Coronavirus

CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV)

The Cardiac Implications of Coronavirus

 

VIDEO: COVID-19 Pneumonia Chest CT Scan Scroll Through

CT Imaging of the 2019 Novel Coronavirus (2019-nCoV) Pneumonia

Chest CT Can Distinguish Negative From Positive Lab Results for COVID-19

VIDEO: CT Sees Increased Use During COVID-19

 

Radiologists Urge Use of Medical Imaging and AI-Powered Solutions to Manage COVID-19

Stroke Scans Could Reveal COVID-19 Infection

Handheld Ultrasound Used to Monitor COVID-19 Patients With Cardiac Complications

Study Looks at CT Findings of COVID-19 Through Recovery

Using Lung X-rays to Diagnose COVID-19

How COVID-19 Affects the Brain in Neuroimaging
 

VIDEO: Lingering Myocardial Involvement After COVID-19 Infection — Interview with Aaron Baggish, M.D.

COVID-19 Can Impact Hearts in Young Children

VIDEO: What Are The Long-term Cardiac Impacts of COVID-19 Infection — Interview with Todd Hurst, M.D.

Find more related clinical content Coronavirus (COVID-19)

Related Content

News | Cardiovascular Business

October 15, 2021 — The American Heart Association (AHA) released a new policy statement that offers policy ...

Home October 15, 2021
Home
Feature | Cardiovascular Business

June 10, 2021 — Diagnostic and Interventional Cardiology (DAIC) magazine has won a prestigious Jesse H. Neal Award for ...

Home June 10, 2021
Home
News | Cardiovascular Business

May 5, 2021 — A late-breaking study presented at the Society for Cardiovascular Angiography and Interventions (SCAI) ...

Home May 05, 2021
Home
News | Cardiovascular Business

March 12, 2021 — Cardinal Health today announced that it is selling its Cordis cardiology and endovascular business to ...

Home March 12, 2021
Home
News | Cardiovascular Business

February 3, 2021 — Modern Vascular is a medical group that has 13 outpatient cath lab clinics to treat peripheral artery ...

Home February 03, 2021
Home
Feature | Cardiovascular Business | Dave Fornell, Editor

December 1, 2020 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC) ...

Home December 01, 2020
Home
News | Cardiovascular Business

September 14, 2020 — New global research released by Abbott takes a deep dive into the barriers of cardiovascular ...

Home September 14, 2020
Home
Videos | Cardiovascular Business

Nick West, M.D., chief medical officer for Abbott, explains the details from a survey of 1,400 patients, physicians and ...

Home September 14, 2020
Home
Feature | Cardiovascular Business | Deb Thompson and Christian Comeau

For a cardiovascular service line leader, addressing challenges in an evolving healthcare climate is a constant ...

Home July 13, 2020
Home
News | Cardiovascular Business

July 8, 2020 – Philips Healthcare and Leeds Teaching Hospitals NHS Trust announced a seven-year managed service ...

Home July 08, 2020
Home
Subscribe Now